Affordable Access

Publisher Website

Dendritic cell immunotherapy in uterine cancer.

Authors
Type
Published Article
Journal
Human Vaccines & Immunotherapeutics
2164-554X
Publisher
Informa UK (Taylor & Francis)
Publication Date
Volume
10
Issue
7
Pages
1822–1827
Identifiers
DOI: 10.4161/hv.28716
PMID: 25424788
Source
Medline
Keywords
  • Dc
  • Wt1
  • Dendritic Cell
  • Electroporation
  • Immunotherapy
  • Uterine Cancer

Abstract

Uterine cancer is the most common pelvic gynecological malignancy. Uterine sarcomas and relapsed uterine carcinomas have limited treatment options. The search for new therapies is urgent. Dendritic cell (DC) immunotherapy holds much promise, though has been poorly explored in uterine cancer. This commentary gives an insight in existing DC immunotherapy studies in uterine cancer and summarizes the possibilities and the importance of the loading of tumor antigens onto DC and their subsequent maturation. However, the sole application of DC immunotherapy to target uterine cancer will be insufficient because of tumor-induced immunosuppression, which will hamper the establishment of an effective anti-tumor immune response. The authors give an overview on the limited existing immunosuppressive data and propose a novel approach on DC immunotherapy in uterine cancer.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments